JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Potential prognostic and immunologic significances of ADAM8 in clear cell renal cell carcinoma

  • 0Department of Urology, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Medicine +

|

January 31, 2025

|

January 31, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

A Disintegrin And Metalloproteinase 8 (ADAM8) is elevated in kidney cancer, correlating with poorer prognosis and immune response. This suggests ADAM8 as a potential target for kidney cancer treatment and immunotherapy.

Area Of Science

  • Oncology
  • Bioinformatics
  • Cancer Research

Background

  • A Disintegrin And Metalloproteinase 8 (ADAM8) is linked to various cancers.
  • Its role in clear cell renal cell carcinoma (ccRCC) requires further investigation.

Purpose Of The Study

  • To investigate the prognostic and immunologic significance of ADAM8 in ccRCC.
  • To explore ADAM8 as a potential therapeutic target in ccRCC.

Main Methods

  • Analysis of ADAM8 expression and prognosis in ccRCC using TCGA, GEO, and IHC.
  • Functional enrichment analysis and CIBERSORT algorithm for pathway and tumor microenvironment analysis.
  • Exploration of immunotherapy response and drug discovery using TCIA and CMAP.

Main Results

  • ADAM8 expression is significantly elevated in ccRCC tissues.
  • Higher ADAM8 levels correlate with poorer prognosis and serve as an independent risk factor.
  • ADAM8 expression is associated with immune cell infiltration, immunotherapy response, and identified potential ccRCC drugs.

Conclusions

  • ADAM8 significantly impacts ccRCC development, progression, immunotherapy, and prognosis.
  • ADAM8 represents a promising prognostic and immunotherapeutic target for ccRCC management.